It's all part of post-marketing surveillance to look at a lot of safety information. Before drugs come on the market, they're tested in a fairly narrow, often homogeneous group. When they come out on the market and you're using them in pediatrics or the elderly or people with kidney dysfunction, they probably haven't been tested in some of those populations, so it's really important to get that information.
Most drug plans, in particular the government drug plans, have formularies and they have restricted access. They want to know that these drugs that are restricted because of either cost or safety concerns are being used appropriately and for the right patients. Without collecting that information, you wouldn't be able to research any of that.